Anti-Dxd Antibodies in ADC Optimization

Dxd (deruxtecan), a highly potent topoisomerase I inhibitor, serves as a cornerstone in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. By delivering precise and potent cytotoxicity directly to cancer cells, Dxd-based ADCs minimize harm to healthy tissues, offering a transformative approach to treatment. However, the development of these ADCs demands rigorous pharmacokinetic (PK) and safety assessments to ensure their efficacy and reliability.

Our specialized anti-Dxd antibodies streamline these critical evaluations, enabling enhanced PK analysis and comprehensive safety testing. By supporting the optimization of ADCs, these antibodies play a pivotal role in advancing cancer therapies, ensuring both safety and therapeutic effectiveness in the fight against cancer.

View All Anti-Dxd Antibodies >>